Use of isoniazid chemoprophylaxis in renal transplant recipients 635 of TB is high. Furthermore, these results have important implication in patients from such areas who are immunosuppressed following other kinds of transplantation and for those who are immunocompromised for any other reason.
Introduction
Renal transplantation is considered the best therapeutic option for end-stage renal disease (ESRD). Infections of various kinds in immunosuppressed organ recipients remain one of the main post-transplant risk factors. Tuberculosis (TB) is one of the most common of these infections. In Pakistan, where the incidence of TB in the general population is amongst the highest in SouthEast Asia (250/100 000) [1] [2] [3] , post-transplant TB infection occurs in 12.4-15.2% of renal transplant recipients in our institution [4, 5] . The use of isoniazid (INH) in immunocompromised patients has been previously reported in studies on variable numbers of patients from both the developing and the developed world, where the prevalence of TB in the general population varies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The number of patients receiving INH in these studies varied between 3 and 53 patients, and all except one used INH in the high-risk group. In one study where they randomized prospectively, 27 patients received INH [10] . Resistance to INH in the general population in these studies varied between 5.5 and 19%. We present the results of the largest prospective randomized study of the use of INH as chemoprophylaxis in renal transplant recipients from any country where TB is endemic.
Patients and methods
Four hundred renal patients who received a living-related transplant between April 2001 and September 2004 were randomized to receive INH for 1 year post-transplant or no prophylaxis. All patients were documented for past history of TB or history of TB in donor or close contacts prior to transplant and followed up clinically for a minimum of 4 years after transplant. Twelve patients dropped out from the study during the first year due to graft loss (10) or patient loss (2), leaving 388 patients who were studied.
Randomization was achieved by using tables for random sampling numbers [21] . CONSORT guidelines [22] were reviewed for the two groups.
All recipients were followed up initially every week, then fortnightly, once a month, every 2 months and subsequently every 3 months, according to the period post-transplant.
As institutional policy, all our recipients received three immunosuppressant drugs for maintenance, usually cyclosporin, azathioprine and prednisolone. Some patients were considered for mycophenolate instead of azathioprine from both groups. Cyclosporin A (CyA) was initially given at a dose of 6 mg/kg/day in two divided doses, and area under the curve (AUC) calculations were performed in all recipients on Day 5 with a target total AUC between 6000 and 7000 ng/ml/h. The target CyA trough was between 250 and 300 during the first 6 months; CyA levels were determined by Clone Enzyme Donor Immuno Assay (CEDIA). The dose of azathioprine varied between 1.5 and 2 mg/kg/day according to how well the recipient tolerated the drug. Prednisolone was initially given at a dose of 0.5 mg/kg/day and tapered to a maintenance dose of 7.5 mg/day ∼12 weeks post-transplantation.
End points for discontinuation of prophylaxis were the development of clinical TB or jaundice. The definition for the diagnosis of TB was reviewed with cochrane [23] , though primarily diagnosis was decided to be made on the basis of one or more of the following criteria:
1. Fever of more than 2 weeks' duration with a negative work up for bacteriological, viral or fungal infections (probable TB).
Positive results of either Mycobacterium Tuberculosis Polymerase
Chain Reaction (MTB PCR), by nucleic acid amplification method, targeting IS6110 (probable TB). 3. Positive AFB smear (definitive TB). 4. Positive MTB culture on conventional media (definitive TB). 5. Radiological findings consistent with TB (probable TB). 6. Histopathological findings consistent with TB (definitive TB). 7. Documented response to anti-TB therapy (probable TB).
The site of TB was recorded according to World Health Organization/International Union Against Tuberculosis and Lung Disease (WHO/IUATLD) definitions [24] . Risks were defined as acute rejection episodes and exposure to anti-rejection therapy. A past history of TB completely or incompletely treated, radiological evidence of past tuberculosis, a past history of TB in the donor and a history of TB in close contacts were recorded in the two groups. A liver profile was obtained at time zero and after 3 months and 6 months and on clinical suspicion of jaundice.
Tuberculin skin testing was not performed in this population prior to transplant.
Comparisons between groups were made using chi-square statistics for categorical variables and two-sided 't' tests for continuous variables. Continuous data are reported as mean ± SD, whereas skewed data are reported as median. Relative risk (RR) was calculated for each category with 95% confidence interval (CI). The number needed to treat (NNT) was calculated along with 95% CI. Statistical significance was identified by a two-sided P-value of < 0.05.
All recipients were informed about the study at the time of transplant, and hospital ethical committee approved the study.
Results
Results were compared in patients developing TB posttransplant in the two groups, the INH prophylaxis group and non-INH prophylaxis group. The primary disease leading to ESRD, comorbidities and HLA (human leucocyte antigen) match with donors were similar in the two groups (Table 1) . The occurrence of clinical TB was compared in recipients with or without having a risk for developing TB (Table 2) . Induction and maintenance immunosuppression protocols as well as anti-rejection therapy regimen were the same in two groups (Table 3) .
One patient from the INH prophylaxis group and 16 from the non-INH prophylaxis group developed TB posttransplantation (P = 0.0003). Infection in the one patient from the INH group who developed TB occurred 6 weeks post-transplantation, and this patient showed no resistance to INH. In the non-INH prophylaxis group, 10 patients (62.5%) developed TB during the first year, 3 (18.75%) during the second year and 3 patients developed TB 2 years after transplantation.
The site of TB was pulmonary in eight and extra pulmonary in nine (three joints/bone, four lymph node, one peritoneal and one disseminated). The diagnosis was definitive in 12 and probable in 5 patients (Table 4) .
One recipient developed transient isolated hyperbilirubinaemia while on INH but did not require discontinuation of INH.
Discussion
Renal transplant recipients are at a higher risk of developing clinically significant mycobacterial infections including TB [25, 26] . TB can develop by reactivation, can be transmitted via the donor organ or can be acquired as an air-borne de novo infection [26] . Rates of infection remain high during the initial post-transplant period because higher doses of immunosuppressants are given at this early post-transplant time. In our past experience of post-transplant TB, 63% of infections occurred during the first post-transplant year [4, 5] . Queipo et al. also experienced a higher rate of TB during the early post-transplant period [19] .
There exists persistence of high rate of post-transplant TB in this endemic region, and previously published studies have shown encouraging results of use of INH as prophylaxis [7, [9] [10] [11] [12] [13] [14] [15] . The only other randomized and prospective trial published from a region where TB is endemic involved only 58 patients in the untreated and 27 patients in the INHtreated group [10] , whereas another study from the region selected patients on dialysis (in randomized fashion) and continued INH for 1 year after transplantation. In this study, there were 92 patients in each group. In the INH group 7 patients and in the placebo group 10 patients developed TB during the first year. Those who developed TB in the INH group had discontinued INH at variable time points during the course of INH prophylaxis, making interpretation of the results difficult [9] .
This highlighted the need for a well-designed study of the use of INH as prophylaxis in this particular population. All recipients included in this study have now been followed up for more than 4 years post-transplant, to identify the incidence of late infection. Randomization of population distributes risks among population and thus strengthens the study. Although risk factors in the two groups in this study were similar, the occurrence of post-transplant TB infection between the two groups was significantly different.
At our institution, tuberculin skin testing was not performed routinely for recipients and donors because of the prevalence of TB in Pakistan and because of risk of anergy in an immunocompromised population due to impaired cellmediated immunity [17, 18, 27] . Transiently elevated hepatic function tests have been described in 9-18% of patients in the general population who receive INH, with a rate of clinically significant hepatotoxicity in 6.8%, though The American Thoracic Society recommends the discontinuation of INH only when a symptomatic patient displays 3-to 5-fold increase in liver enzymes levels [28, 29] . This was not our experience in this study.
The present study demonstrates effective reduction in cases of post-transplant TB with use of INH prophylaxis with absolute risk reduction of 0.052 with 95% CI 0.019-0.086, and NNT of 19.067 with 95% CI of 12-53.
Conclusion
The results of our study provide evidence that prophylactic INH for 1 year following renal transplantation significantly reduces the incidence of TB, and could be considered mandatory in a high-risk population from a region where TB is endemic. Furthermore, the results of this study have important implications for other transplant recipients and in patients who are immunocompromised for other reason.
